PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.00
Bid: 32.40
Ask: 32.90
Change: 0.00 (0.00%)
Spread: 0.50 (1.543%)
Open: 32.60
High: 33.50
Low: 32.20
Prev. Close: 33.00
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - EKF Diagnostics Holdings Plc

25 Aug 2015 11:30

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: HARGREAVE HALE LIMITED (for Discretionary Clients)
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

EKF DIAGNOSTICS HOLDINGS PLC
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A
(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

24 AUGUST 2015
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

NO

If YES, specify which: N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: ORDINARY 1p

Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 11,335,359 2.6857
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

11,335,359 2.6857

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit
NONE

(b) Cash-settled derivative transactions

Class of relevant security Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities Price per unit
NONE

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type

e.g. American, European etc.

Expiry date Option money paid/ received per unit
NONE

(ii) Exercise

Class of relevant security Product description

e.g. call option

Exercising/ exercised against Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)
NONE

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 25 AUGUST 2015
Contact name: DAVID CLUEIT

HARGREAVE HALE LTD

Telephone number: 01253 754739

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150825005652/en/

Copyright Business Wire 2015

Date   Source Headline
25th Aug 20152:58 pmRNSForm 8.3 - EKF Diagnostics Holdings plc
25th Aug 20152:36 pmBUSForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 20152:15 pmRNSForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 20151:10 pmRNSHolding(s) in Company
25th Aug 201511:54 amPRNForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 201511:30 amBUSForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 201510:52 amRNSHolding(s) in Company
24th Aug 201511:19 amRNSForm 8.3 - EKF Diagnostics Holdings Plc
24th Aug 20157:01 amRNSAnnouncement under rule 2.4 of the Takeover Code
24th Aug 20157:00 amRNSFurther non-binding proposal
18th Aug 201512:00 pmRNSConclusion of Strategic Review
18th Aug 201511:55 amRNSTrading update
10th Aug 20159:25 amRNSHolding(s) in Company
19th May 20152:26 pmRNSResult of AGM
13th May 20157:00 amRNSLaunch of PrecisionPath Colon
1st May 20153:15 pmRNSPosting of Annual Report & Notice of AGM
24th Apr 20154:44 pmRNSHolding(s) in Company
21st Apr 20151:17 pmRNSData for PointMan Technology presented at AACR
8th Apr 201511:41 amRNSHolding(s) in Company
8th Apr 201511:36 amRNSHolding(s) in Company
2nd Apr 20157:00 amRNSShareholder update
26th Mar 20153:47 pmRNSHolding(s) in Company
25th Mar 20153:05 pmRNSHolding(s) in Company
19th Mar 20159:40 amRNSHolding(s) in Company
18th Mar 20153:41 pmRNSHolding(s) in Company
16th Mar 20157:00 amRNSFinal Results
2nd Mar 20157:00 amRNSCollaboration to improve colon cancer treatment
23rd Feb 20157:00 amRNSNotice of results & investor results presentation
2nd Feb 20157:00 amRNSChange of Adviser
28th Jan 20157:00 amRNSTrading update
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
5th Jan 20157:00 amRNSPayment of DiaSpect's deferred consideration
17th Dec 20147:00 amRNSTrading update & potential Board appointment
11th Nov 20144:46 pmRNSHolding(s) in Company
1st Oct 201411:36 amRNSDirector/PDMR Shareholding
23rd Sep 20147:00 amRNSUS collaboration to develop blood tests for cancer
15th Sep 20147:00 amRNSHalf Yearly Report
15th Aug 20147:00 amRNSDirectorate Change
13th Aug 20147:00 amRNSNotice of results and investor briefing
23rd Jul 20147:00 amRNSTrading update
8th Jul 20147:00 amRNSContract Win and Regulatory Approval
13th Jun 201412:53 pmRNSHolding(s) in Company
9th Jun 20145:59 pmRNSGrant of Share Options
6th Jun 20142:46 pmRNSHolding(s) in Company
2nd Jun 20144:15 pmRNSHolding(s) in Company
2nd Jun 20147:00 amRNSMajor step towards detecting cancer in blood
2nd Jun 20147:00 amRNSDirectorate Change
27th May 20143:59 pmRNSHolding(s) in Company
23rd May 201411:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.